Product
Gemcitabine platinum + Erlotinib
1 clinical trial
3 indications
Indication
cancerIndication
Non-Small Cell LungIndication
EGFR gene mutationClinical trial
Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI TreatmentStatus: Recruiting, Estimated PCD: 2024-12-01